Correction to: Nature Communications https://doi.org/10.1038/s41467-024-53223-3, published online 25 November 2024
The original version of the Transparent Peer Review File associated with this Article was updated shortly after publication to correct an error on page 21 wherein “Reduction: 64.7% [46.5–80.3] (22/34)” was incorrectly presented as “Reduction: 64.7% [45.6–80.3] (22/34)”.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Siena, S., Raghav, K., Masuishi, T. et al. Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun 16, 704 (2025). https://doi.org/10.1038/s41467-025-56170-9
Published:
Version of record:
DOI: https://doi.org/10.1038/s41467-025-56170-9
